Vise Technologies Inc. Makes New $613,000 Investment in Haemonetics Corporation $HAE

Vise Technologies Inc. acquired a new stake in shares of Haemonetics Corporation (NYSE:HAE) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,822 shares of the medical instruments supplier’s stock, valued at approximately $613,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of America Corp DE bought a new position in Haemonetics in the second quarter worth approximately $33,326,000. Assenagon Asset Management S.A. raised its holdings in shares of Haemonetics by 1,191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after purchasing an additional 418,470 shares in the last quarter. William Blair Investment Management LLC bought a new stake in shares of Haemonetics in the 2nd quarter valued at about $24,906,000. Bank of New York Mellon Corp purchased a new position in Haemonetics during the second quarter valued at approximately $21,566,000. Finally, Dimensional Fund Advisors LP increased its holdings in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after buying an additional 233,119 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 1.3%

HAE stock opened at $120.72 on Thursday. Haemonetics Corporation has a 12-month low of $51.00 and a 12-month high of $132.00. The business’s 50-day moving average is $112.54 and its 200 day moving average is $80.81. The company has a current ratio of 2.84, a quick ratio of 1.83 and a debt-to-equity ratio of 1.24. The stock has a market cap of $5.50 billion, a price-to-earnings ratio of 54.13, a PEG ratio of 2.45 and a beta of 0.63.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The business had revenue of $357.76 million during the quarter, compared to analysts’ expectations of $345.15 million. During the same period in the prior year, the business earned $1.27 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Haemonetics Corporation will post 5.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HAE has been the subject of several recent research reports. Citigroup boosted their price target on Haemonetics from $123.00 to $149.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Barrington Research increased their target price on shares of Haemonetics from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. BTIG Research upped their price target on Haemonetics from $130.00 to $142.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. JPMorgan Chase & Co. raised their price objective on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Mizuho set a $165.00 price target on Haemonetics in a report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.38.

Haemonetics Profile

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.